# Zika Virus Outbreak and NIAID Research Response

## May 20, 2016

#### Cristina Cassetti, Ph.D.


Translational Science Program Director Virology Branch Division of Microbiology and Infectious Diseases National Institute of Allergy and Infectious Diseases National Institutes of Health ccassetti@niaid.nih.gov





# **Zika Virus**


- Single stranded, enveloped RNA Virus
  - Family *Flaviviridae,* Genus *Flavivirus*




- Closely related to dengue, yellow fever, Japanese encephalitis and West Nile viruses
- Transmitted to humans primarily by Aedes species mosquitoes


# **Symptoms of Zika Virus Infection**

#### 4 in 5 individuals asymptomatic






Virus first isolated from a monkey in the Zika forest of Uganda in 1947



#### First human cases reported in Nigeria in 1952


# Zika Virus Spread, 1947-2016



# **Countries and Territories with Active Zika Virus Transmission – April 2016**



## Marked Increase in Microcephaly Cases in Brazil




AS Fauci/ NIAID

Source: Brazilian MOH; data as of 5/4/2016.

# **Microcephaly**

- An occipitofrontal circumference at least 2 standard deviations below the mean (definitions differ)
- Associated with reduced life expectancy and abnormal neurocognitive development
- Major etiologies include:
  - Genetic anomalies
  - Fetal alcohol syndrome
  - Other maternal factors (malnutrition, endocrine disorders)
  - Maternal infections (including cytomegalovirus, toxoplasmosis, rubella)



# **Microcephaly Attributed to Zika**



Normal infant brain and head size



#### Microcephaly, Colombia 2015

Images: LatinAmericanScience.org

# Neonatal Manifestations of Congenital Zika Virus Infection

- Microcephaly
- Intracerebral calcifications (mostly periventricular)
- Hearing loss
- Vision abnormalities
- Lissencephaly
- Pachygyria
- Ventricular enlargement
- Arthrogryposis
- Muscular atrophy



# **Neurological Disease Caused by Zika**

# Guillain-Barré Syndrome Acute, immune-mediated neuropathy

- Acute Myelitis
  - Spinal cord inflammation
- Meningoencephalitis



National Institute of Allergy and Infectious Diseases


**Damaged myelin** 

# **NIAID Research Response**

- Leveraging existing Program on Flaviviruses to rapidly start research on Zika
- Since January 2016, over 40 projects initiated to:
  - Understand basic biology/structure/evolution of virus and competence of the mosquito vectors
  - Develop vaccines, diagnostics, therapeutics and vector control strategies
  - Elucidate the mechanism of pathogenesis and congenital infection



## **Developing Improved Diagnostics Through Mutagenesis**




# **Antiviral Screening Program**

- Developed Zika in vitro screening assay
- Tested 87 antiviral compounds with known activity against other flaviviruses
  - 14 have high to moderate activity against Zika virus
- Promising drug candidates are being further tested in Zika mouse model
  - BCX4430 found to protect immune-deficient mice infected with Zika virus
- Collaborating with NCATS and Gates Foundation to develop high throughput screening assay to screen existing libraries of approved drugs



# **Zika Vaccine Development Timeline**



## **Biomedical Research Response:** Vector Control

- Vector competence: Ability of mosquitoes other than Aedes aegypti to carry and transmit Zika virus
  - **Novel insecticides**

Novel vector control methods – genetically modified mosquitoes; *Wolbachia*-infected mosquitoes

# **Pathogenesis Studies**

- Natural history, cohort studies in pregnant and nonpregnant population
  - Role of existing flavivirus immunity
  - Role of asympthomatic infections in congenital disease
  - Viral loads/dynamics in different bodily fluids (transmission)
  - Long term observational studies in babies born from Zikainfected mothers
- Development of animal models
  - Mice
  - Hamsters
  - NHPs ( Dave O' Connor)

